Rigel Pharmaceuticals Inc RIGL
News
Rigel Reports Third Quarter 2026 Financial Results
Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition
Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results
Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel to Participate in Upcoming September Investor Conferences
Arvinas, Pfizer Tap Rigel Pharmaceuticals to Bring Veppanu to Market

